The serum concentrations of CA 125 and placental alkaline phosphatase were analyzed in 16 patients with ovarian cancer. Increased serum levels of CA 125 and placental alkaline phosphatase were observed in 75% and 50% of the cancer patients, respectively. The serum levels of these tumor markers were not correlated, supporting their distinct antigenic nature. CA 125 seems to be a more promising tumor marker for ovarian cancer than placental alkaline phosphatase.
DaviesJ.O., StirratG.M., SunderlandC.A.: Are CA 125 and placental alkaline phosphatase the same antigen? Am.J. Obstet. Gynecol., 151: 419–420, 1985.
3.
EerdekensM.W., NouwenE.J., PolletD.E., BriersT.W., DeBroeM.E.: Placental alkaline phosphatase and cancer antigen 125 in sera of patients with benign and malignant diseases.Clin. Chem., 31: 687–690, 1985.
4.
HeinonenP.K., TonttiK., KoivulaT., PystynenP.:Tumour-associated antigen CA 125 in patients with ovarian cancer.Br. J. Obstet. Gynecol., 92: 528–531. 1985.
5.
KallioniemiO.-P., HeinonenP.K., PystynenP., KoivulaT.: Evaluation of the value of fluorometric serum heat stable alkaline phosphatase assay in patients operated for ovarian tumours.Tumour Biol., 6: 213–219, 1985.
